The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2021 | From myeloma precursors to late relapses, where do BiTEs fit?
Bispecific T-cell engagers (BiTEs) offer a promising immunotherapeutic approach for multiple myeloma. BiTEs link endogenous T-cells to tumor-expressed antigens to activate a patient’s immune system against their own cancer. Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, talks on the latest developments using BiTEs and how they may represent a new era for the treatment of myeloma. Prof. Martin shares his thoughts on the potential of sequential therapy using BiTEs with various targets. He also notes that BiTEs may blanket the myeloma space, with potential utility in smoldering myeloma, first-line therapy, and early and late relapses. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
